简单介绍

黄世亮,1973年,博士,博导,副教授。1995年于沈阳药科大学获得化学制药专业学士学位,并于1998年获该校药物化学硕士学位,2006年于中山大学获有机化学博士学位。1998年在中山大学任教至今。2010-2011年国家公派英国诺丁汉大学药学院访问学者。

科研项目

1)选择性靶向Top IIa的ATPase的新型抗肿瘤曼宋酮类化合物的设计、合成及机制研究(21272288/B020601),国家自然科学基金,2013.1-2016.12.

2)基于FP和TR-FRET高通量筛选技术:靶向Top IIa ATPase新先导物的发现及结构改造(2015A030313120),省自然科学基金面上项目,2014年10月至 2017年9月

3)选择性靶向Top IIα的ATPase的新型抗肿瘤曼宋酮类化合物的设计、合成及机制研究(21272288), 国家自然科学基金,2013.1-2016.12.

4) 靶向TopIIα ATPase位点的新型曼宋酮类化合物的设计、合成及机制研究,药用资源化学与药物分子工程教育部重点实验室资助课题(CMEMR2012-B02), 2012.6-2015.5

5) 基于mRNA 5’UTR G-四链体调控β-分泌酶的抗阿尔茨海默症先导化合物的发现与分子机制研究(81273433/H3007),国家自然科学基金,参与人,2013.1-2016.12

6)基于TOPII的ATP活性位点的新曼宋酮F类似物的设计、合成与活性研究(A2011155),广东省医学研究基金,2011-2013

7)新型抗肿瘤天然产物Mansonone F衍生物的合成、构效关系和作用机制研究(30701050), 国家自然科学基金, 2008.1-2010.12

8) 曼宋酮F衍生物的抗肿瘤作用构效关系和作用机制研究(7301303), 广东省自然科学基金, 2007.10-2009.10

9)具抗菌和抗肿瘤作用的天然产物曼宋酮 E、F的结构改造及活性筛选 (B2007033), 广东省医学科研基金, 2007.9-2009.9

论著专利

1)Xie, H.-T.; Zhou, D.-C.; Mai, Y.-W.; Huo, L.; Yao, P.-F.; Huang, S.-L.*; Wang, H.-G.; Huang, Z.-S.; Gu, L.-Q. Construction of the oxaphenalene skeletons of mansonone F derivatives through C–H bond functionalization and their evaluation for anti-proliferative activities. RSC Adv. 2017, 7, 20919-20928.

 2)Li, P. H.; Zeng, P.; Chen, S. B.; Yao, P. F.; Mai, Y. W.; Tan, J. H.; Ou, T. M.; Huang, S. L.*; Li, D.; Gu, L. Q.; Huang, Z. S.*Synthesis and Mechanism Studies of 1,3-Benzoazolyl Substituted Pyrrolo[2,3-b]pyrazine Derivatives as Nonintercalative Topoisomerase II Catalytic Inhibitors. J Med. Chem. 2016, 59, 238-52.

3)Zhai, P.; Xia, C. L.; Tan, J. H.; Li, D.; Ou, T. M.; Huang, S. L.*; Gu, L. Q.; Huang, Z. S.* Syntheses and evaluation of asymmetric curcumin analogues as potential multifunctional agents for the treatment of Alzheimer's disease. Current Alzheimer research 2015, 12, 403-14.

4) Yao, B. L.; Mai, Y. W.; Chen, S. B.; Xie, H. T.; Yao, P. F.; Ou, T. M.; Tan, J. H.; Wang, H. G.; Li, D.; Huang, S. L.*; Gu, L. Q.; Huang, Z. S.* Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors. Eur. J. Med. Chem.  2015, 92, 540-53.   

 5)Zhuo, S. T., Li, C. Y., Hu, M. H., Chen, S. B., Yao, P. F., Huang, S. L.,* Ou, T. M., Tan, J. H., An, L. K., Li, D., Gu, L. Q., and Huang, Z. S.* Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II, Org. Biomol. Chem. 2013,11(24), 3989-4005.

2)      Huang, Z. H., Zhuo, S. T., Li, C. Y., Xie, H. T., Li, D., Tan, J. H., Ou, T. M., Huang, Z. S., Gu, L. Q., and Huang, S. L.* Design, synthesis and biological evaluation of novel mansonone E derivatives prepared via CuAAC click chemistry as topoisomerase II inhibitors, Eur. J. Med. Chem. 2013,68C, 58-71.

3)      Chen, Y. P., Zhang, Z. Y., Li, Y. P., Li, D., Huang, S. L.,* Gu, L. Q., Xu, J., and Huang, Z. S. () Syntheses and evaluation of novel isoliquiritigenin derivatives as potential dual inhibitors for amyloid-beta aggregation and 5-lipoxygenase, Eur. J. Med. Chem. 2013, 66, 22-31.

4)      Li, Y. P., Weng, X., Ning, F. X., Ou, J. B., Hou, J. Q., Luo, H. B.,* Li, D., Huang, Z. S., Huang, S. L.,* and Gu, L. Q. 3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method, J. Mol. Graph. Model. 2013, 41, 61-67.

5)      Li, Y.-P., Ning, F.-X., Yang, M.-B., Li, Y.-C., Nie, M.-H., Ou, T.-M., Tan, J.-H., Huang, S.-L.,* Li, D., Gu, L.-Q., Huang, Z.-S. Syntheses and characterization of novel oxoisoaporphine derivatives as dual inhibitors for cholinesterases and amyloid beta aggregation. Eur. J. Med. Chem., 2011. 46(5): 1572-1581

6)      Fang Xian Ning, Xiang Weng, Shi Liang Huang,* Li Jun Gu, Zhi Shu Huang, * Lian Quan Gu.A facile and efficient method for hydroxylation of azabenzanthrone compounds.Chin. Chem. Lett. 2011,22(1), 41-44

7)      Wei-bin Wu, Jie-bin Ou, Zhi-shu Huang, Shuo-bin Chen, Tian-miao Ou, Jia-heng. Tan, Ding Li, Liu-lan. Shen, Shi-liang Huang*, Lian-quan Gu and Zhi-shu Huang, Eur. J. Med. Chem. 2011, 46, 3339-3347.

8)      Zhong Liu, Shi-Liang Huang, Man-Mei Li, Zhi-Shu Huang, Kin Sing Lee*, Lian-Quan Gu*. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity. Chem-Bio. Interac. 2009, 177(1), 48-57

9)      Hua-pei Jian, Xing-yuan Wang, Zhi-shu Huang, Shi-liang Huang,*, Lian-quan Gu. A Facile Synthesis of Novel Heteropolycyclic Pyrazines and Oxazoles Mechanistic Studies of 2,3-Dihydrobenzo[de]chromene-7,8-dione with Amines. Heterocycles. 2008,75(7),1773-1778.

10)   Shi-Liang Huang, Yi Luo, Zhi-Shu Huang, Xing-Yuan Wang, Xian-Zhang Bu, Pei-Qing Liu, Lin Ma, Bing-Fen Xie, Zong-Chao Liu, Yue-Ming Li, Albert S. C. Chand, Lian-Quan Gu. Synthesis and Cytotoxicity of 9-Substitued benzo[de] chromene -7,8-dione and 5-benzyl -9- Substitued benzo[de]chromene-7,8-dione. Synthetic Communications. 2006, 36(18), 2667-2684.

11)   Shi Liang Huang, Yi Luo, Zhi Shu Huang, Xian Zhang Bu, Pei Qing Liu, Lin Ma, Yue Ming Li, Albert S. C. Chan, Lian Quan Gu. The Mechanism on Cyclization, Debenzylation and Oxidation of 1-[1- (Benzyloxy)-3- methylnaphthalen-4- yloxy]propan-2-one. Chin. Chem. Lett.2006, 17(6), 769-772.